Survival in patients with malignant neoplasms of pancreatoduododenobiliary zone complicated by obstruction of bile duct

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

There were analyzed the survival and mortality of 227 patients with malignant neoplasms of pancreatoduodenobiliary zone complicated by obstruction of bile duct syndrome for the period from 01.01.2014 to 01.05.2018 divided into 4 groups. The first group consisted of 20 patients who underwent radical operative treatment of malignant neoplasms of the pancreatoduodenobiliary zone without the use of minimally invasive biliary decompression as preoperative preparation; the second group included 34 patients who had minimally invasive biliary decompressionas preoperative preparationfor radical surgery; the third group included 121 patients who had palliative operative treatment of malignant neoplasms of the pancreatoduodenobiliary zone without the use of minimally invasive biliary decompression; the fourth group consisted of 54 patients who underwent palliative operations with the use of mini-invasive biliary decompression. After paired comparative analysis of postoperative survival and lethality, it was revealed a statistically significant increase in the average life expectancy and a decrease in postoperative mortality in patients who underwent radical surgery with the use of minimally invasive decompression technologies for bile ducts compared with all the other groups; a statistically significant increase in life expectancy and a reduction in postoperative mortality in patients who underwent palliative surgery with the use of mini-invasive biliary decompression compared to the group of patients who underwent open palliative surgeries. In patients who underwent radical surgical treatment without prior application of minimally invasive procedures for decompression of the biliary tree, there was no statistically significant increase in mean life expectancy and a decrease in postoperative mortality in comparison with the group of patients who underwent palliative operations with the use of mini-invasive bile decompressiontechnologies.

Full Text

Restricted Access

About the authors

A. Е. Tseimakh

Altai State Medical University

Author for correspondence.
Email: alevtsei@rambler.ru
ORCID iD: 0000-0002-1199-3699
Russian Federation, 656038, Barnaul

А. F. Lazarev

Altai State Medical University; Altai branch of N.N. Blokhin Russian Cancer Research Center

Email: alevtsei@rambler.ru
ORCID iD: 0000-0003-1080-5294
Russian Federation, 656038, Barnaul; 656049, Barnau

E. L. Sekerzhinskaya

Altai branch of N.N. Blokhin Russian Cancer Research Center

Email: alevtsei@rambler.ru
ORCID iD: 0000-0002-8271-7528
Russian Federation, 656049, Barnaul

N. К. Bedian

State Hospital #5

Email: alevtsei@rambler.ru
ORCID iD: 0000-0002-8271-7528
Russian Federation, 656045, Barnaul

V. А. Kurtukov

State Hospital #5

Email: alevtsei@rambler.ru
ORCID iD: 0000-0002-5582-1178
Russian Federation, 656045, Barnaul

V. N. Teplukhin

State Hospital #5

Email: alevtsei@rambler.ru
ORCID iD: 0000-0003-0788-1421
Russian Federation, 656045, Barnaul

Ya. N. Shoykhet

Altai State Medical University

Email: alevtsei@rambler.ru
ORCID iD: 0000-0002-5253-4325
Russian Federation, 656038, Barnaul

References

  1. Kaprin A.D., Starinskiy V.V., Petrova G.V., eds. Status of oncological care for the population of Russia in 2015. Moscow: MSIOI named after. P.A. Herzen, branch of the NMICR of the Russian Ministry of Health. 2017. (in Russian)
  2. National Comprehensive Cancer Network. NCCN Guidelines. Version 2.2015. Pancreatic Adenocarcinoma. Avalable at: http://www.nccn.org (accessed 24 March 2018).
  3. Kaprin A.D., Starinskiy V.V., Petrova G.V., eds. Status of oncological care for the population of Russia in 2016. Moscow: MSIOI named after. P.A. Herzen, branch of the NMICR of the Russian Ministry of Health. 2017. (in Russian)
  4. Kaprin A.D., Starinskiy V.V., Petrova G.V., eds. Status of oncological care for the population of Russia in 2017. Moscow: MSIOI named after. P.A. Herzen, branch of the NMICR of the Russian Ministry of Health. 2018. (in Russian).
  5. Yeo T.P. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin. Oncol. 2015; 42: 8–18.
  6. Clinical recommendations Biliary cancer Association of oncologists Russia (2012). Available at: http://oncology-association.ru/docs/biliarniy_rak.pdf (accessed 24 March 2018). (in Russian)
  7. Clinical recommendations Cancer of the pancreas Association of oncologists Russia (2012). Available at: http://oncology-association.ru/docs/rak_podzheludochnoy_zhelezy.pdf (accessed 24 March 2018). (in Russian)
  8. Ducreux M., Cuhna A. Sa., Caramella C. et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015; 26: 56–68.
  9. Valle J. W., Borbath I., Khan S. A. et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016; 27: 28–37.
  10. Syndrome of mechanical obstruction of bile duct: medical care for patients in the Krasnodar Region (Regional clinical recommendations). Russian Society of Surgeons (2016). Available at: http://www.xn––9sbdbejx7bdduahou3a5d.xn–p1ai/upload/zheltuhi-krasnodar-2016.pdf (accessed 24 March 2018) (in Russian)
  11. Delpero J.R., Bachellier P., Regenet N. et al. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB (Oxford). 2014; 16: 20–33
  12. Chistyakova S.S. ed. Oncology for practicing doctors. Мoscow: Avtorskaya akademiya; 2009. (in Russian)
  13. Fujii-Lau L.L., Bamlet W.R., Eldrige J.S. et al. Impact of celiac neurolysis on survival in patients with pancreatic cancer. Gastrointest. Endosc. 2015; 82:46–56.
  14. Yeo C.J., Cameron J.L., Lillemoe K.D. et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann. Surg. 2002; 236: 355–66. discussion 366–8.
  15. Howard T.J., Krug J.E., Yu J. et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer. J. Gastrointest. Surg. 2006; 10: 1338–45. discussion 1345-46.
  16. Schmassmann A., von Gunten E., Knuchel J. et al. Wallstents versus plastic stents in malignant biliary obstruction: effects of stent patency of the first and second stent on patient compliance and survival. Am. J. Gastroenterol. 1996; 91: 654–9.
  17. Smeenk H.G., van Eijck C.H., Hop W.C. et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann. Surg. 2007; 246: 734–40
  18. Huang L., Jansen L., Balavarca Y. et al. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study. BMC Med. 16, 125 (2018). https://doi.org/10.1186/s12916-018-1120-9.
  19. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015; 65 (2): 87–108.
  20. Malvezzi M., Carioli G., Bertuccio P., Rosso T., Boffetta P., Levi F., La Vecchia C., Negri E. European cancer mortality predictions for the year 2016 with focus on leukaemias. Ann.Oncol. 2016; 27 (4): 725–31.
  21. Ferlay J., Partensky C., Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016; 55 (9–10): 1158–60.
  22. Lepage C., Capocaccia R., Hackl M., Lemmens V., Molina E., Pierannunzio D., Sant M., Trama A., Faivre J., Grouph E.-W. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999−2007: results of EUROCARE-5. Eur. J. Cancer. 2015; 51 (15): 2169–78.
  23. Wolfgang C.L., Herman J.M., Laheru D.A., Klein A.P., Erdek M.A., Fishman E.K., Hruban R.H. Recent progress in pancreatic cancer. CA Cancer J. Clin. 2013; 63(5): 318–48.
  24. Ryan D.P., Hong T.S., Bardeesy N. Pancreatic adenocarcinoma. N. Engl. J. Med. 2014; 371 (22): 2140–1.
  25. Tempero M.A., Malafa M.P., Behrman S.W., Benson A.B. 3rd, Casper E.S., Chiorean E.G., Chung V., Cohen S.J., Czito B., Engebretson A. et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J. Natl.Compr. Cancer Netw. 2014; 12 (8): 1083–93.
  26. Ducreux M., Cuhna A.S., Caramella C., Hollebecque A., Burtin P., Goere D., Seufferlein T., Haustermans K., Van Laethem J.L., Conroy T. et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann.Oncol. 2015; 26 (Suppl 5): v56–68.
  27. Sohal D.P., Mangu P.B., Khorana A.A., Shah M.A., Philip P.A., O’Reilly E.M., Uronis H.E., Ramanathan R.K., Crane C.H., Engebretson A. et al. Metastatic pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2016; 34 (23): 2784–96.
  28. Khorana A.A., Mangu P.B., Berlin J., Engebretson A., Hong T.S., Maitra A., Mohile S.G., Mumber M., Schulick R., Shapiro M. et al. Potentially curable pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin.Oncol. 2016; 34 (21): 2541–56.
  29. Balaban EP., Mangu P.B., Khorana A.A., Shah M.A., Mukherjee S., Crane C.H., Javle M.M., Eads J.R., Allen P., Ko A.H. et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2016; 34 (22): 2654–68.
  30. Evans D.B., George B., Tsai S. Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multimodality therapy. Ann .Surg. Oncol. 2015; 22 (11): 3409–13.
  31. Huang L., Jansen L., Balavarca Y., Molina-Montes E., Babaei M., van der Geest L., Lemmens V., Van Eycken L., De Schutter H., Johannesen T.B. et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut. 2017. https://doi.org/10.1136/gutjnl-2017-314828. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29158237 (accessed 10 January 2018).
  32. De Angelis R., Sant M., Coleman M.P., Francisci S., Baili P., Pierannunzio D., Trama A., Visser O., Brenner H., Ardanaz E. et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE–5-a population-based study. Lancet.Oncol. 2014; 15 (1): 23–34.
  33. Asbun H.J., Conlon K., Fernandez-Cruz L., Friess H., Shrikhande S.V., Adham M., Bassi C., Bockhorn M., Buchler M., Charnley R.M. et al. When to perform a pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery. Surgery. 2014; 155 (5): 887–92.
  34. Sirri E., Castro F.A., Kieschke J., Jansen L., Emrich K., Gondos A., Holleczek B., Katalinic A., Urbschat I., Vohmann C. et al. Recent trends in survival of patients with pancreatic Cancer in Germany and the United States. Pancreas. 2016; 45 (6): 908–14.
  35. Brenner H., Gondos A., Arndt V. Recent major progress in long-term cancer patient survival disclosed by modeled period analysis. J. Clin. Oncol. 2007; 25 (22): 3274–80.
  36. Loehrer P.J. Sr, Feng Y., Cardenes H., Wagner L., Brell J.M., Cella D., Flynn P., Ramanathan R.K., Crane C.H., Alberts S.R., et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 2011; 29 (31): 4105–12.
  37. Hammel P., Huguet F., van Laethem J.L., Goldstein D., Glimelius B., Artru P., Borbath I., Bouche O., Shannon J., Andre T. et al. Effect of chemoradiotherapyvs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016; 315 (17): 1844–53.
  38. Suker M., Beumer B.R., Sadot E., Marthey L., Faris J.E., Mellon E.A., El-Rayes B.F., Wang-Gillam A., Lacy J., Hosein P.J. et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016; 17 (6): 801–10.
  39. Kim Y., Kim S.C., Song K.B., Kim J., Kang D.R., Lee J.H., Park K.M., Lee Y.J. Improved survival after palliative resection of unsuspected stage IV pancreatic ductal adenocarcinoma. HPB (Oxford). 2016; 18 (4): 325–31.
  40. Krautz C., Nimptsch U., Weber G.F., Mansky T., Grutzmann R. Effect of hospital volume on in-hospital morbidity and mortality following pancreatic surgery in Germany. Ann.Surg. 2018; 267 (3): 411–7.
  41. van der Geest LG, Besselink M.G., van Gestel Y.R., Busch O.R., de Hingh I.H., de Jong K.P., Molenaar I.Q., Lemmens V.E. Pancreatic cancer surgery in elderly patients: balancing between short-term harm and long-term benefit. A population-based study in the Netherlands. Acta Oncol. 2016; 55 (3): 278–85.
  42. Barbas A.S., Turley R.S., Ceppa E.P., Reddy S.K., Blazer D.G. 3rd, Clary B.M., Pappas T.N., Tyler D.S., White R.R., Lagoo S.A. Comparison of outcomes and the use of multimodality therapy in young and elderly people undergoing surgical resection of pancreatic cancer. J. Am. Geriatr. Soc. 2012; 60 (2): 344–50.
  43. Pulte D, Redaniel MT, Brenner H, Jeffreys M. Changes in survival by ethnicity of patients with cancer between 1992-1996 and 2002-2006: is the discrepancy decreasing? AnnOncol. 2012; 23 (9): 2428–34.
  44. de Wilde R.F., Besselink M.G., van der Tweel I., de Hingh I.H., van Eijck C.H., Dejong C.H., Porte R.J., Gouma D.J., Busch O.R., Molenaar I.Q., et al. Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality. Br. J. Surg. 2012; 99 (3): 404–10.
  45. Lemmens V.E., Bosscha K., van der Schelling G., Brenninkmeijer S., Coebergh J.W., de Hingh I.H. Improving outcome for patients with pancreatic cancer through centralization. Br. J. Surg. 2011; 98 (10): 1455–62.
  46. van der Geest L.G., van Rijssen L.B., Molenaar I.Q., de Hingh I.H., Groot Koerkamp B., Busch O.R., Lemmens V.E., Besselink M.G. Volume-out come relationships in pancreatoduodenectomy for cancer. HPB (Oxford). 2016; 18 (4): 317–24.
  47. Shi S., Hua J., Liang C., Meng Q., Liang D. Xu J., Ni Q., Yu X. Proposed modification of the 8th edition of the AJCC staging system for pancreatic ductal adenocarcinoma. Ann. Surg. 2018. https://doi.org/10.1097/SLA.000000000002668.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Comparison of the survival curves of patients after radical surgery without prior HHC (group 1) and with HHC (group 2)

Download (76KB)
Indexing metadata
3. Fig. 2. Comparison of the survival curves of patients after radical surgery with preliminary HHHS (group 2) and after palliative surgery using minimally invasive bile duct surgery (group 4)

Download (80KB)
Indexing metadata
4. Fig. 3. Comparison of the survival curves of patients after a radical operation without preliminary ChCHS (group 1) and after a palliative operation using minimally invasive bile duct operations (group 4)

Download (72KB)
Indexing metadata
5. Fig. 4. Comparison of the survival curves of patients after palliative surgery without the use of biliary surgery (group 3) and with the use of biliary surgery (group 4)

Download (76KB)
Indexing metadata
6. Fig. 5. Comparison of the survival curves of patients with stage IIa of the underlying disease after radical surgery without preliminary ChCHS (group 1) and with ChChHS (group 2) and after palliative surgery without and using biliary surgery (3rd and 4th Group)

Download (95KB)
Indexing metadata
7. Fig. 6. Comparison of the survival curves of patients with stage III of the underlying disease III after radical surgery without preliminary ChCHS (group 1) and with ChChHS (group 2) and after palliative surgery without and using biliary surgery (3rd and 4th groups)

Download (82KB)
Indexing metadata
8. Fig. 7. Comparison of the survival curves of patients with the stage of the underlying disease IV after palliative surgery without the use of bile duct operations (3rd group) and with the use of bile duct surgery (4th group)

Download (75KB)
Indexing metadata

Copyright (c) 2020 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 86496 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ЭЛ № ФС 77 - 80673 от 23.03.2021 г.